Last reviewed · How we verify

Colistin Sodium Methanesulfonate plus Fosfomycin

Chiang Mai University · FDA-approved active Small molecule Quality 1/100

Colistin Sodium Methanesulfonate plus Fosfomycin is a Small molecule drug developed by Chiang Mai University. It is currently FDA-approved. Also known as: Colistin plus fosfomycin.

At a glance

Generic nameColistin Sodium Methanesulfonate plus Fosfomycin
Also known asColistin plus fosfomycin
SponsorChiang Mai University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Colistin Sodium Methanesulfonate plus Fosfomycin

What is Colistin Sodium Methanesulfonate plus Fosfomycin?

Colistin Sodium Methanesulfonate plus Fosfomycin is a Small molecule drug developed by Chiang Mai University.

Who makes Colistin Sodium Methanesulfonate plus Fosfomycin?

Colistin Sodium Methanesulfonate plus Fosfomycin is developed and marketed by Chiang Mai University (see full Chiang Mai University pipeline at /company/chiang-mai-university).

Is Colistin Sodium Methanesulfonate plus Fosfomycin also known as anything else?

Colistin Sodium Methanesulfonate plus Fosfomycin is also known as Colistin plus fosfomycin.

What development phase is Colistin Sodium Methanesulfonate plus Fosfomycin in?

Colistin Sodium Methanesulfonate plus Fosfomycin is FDA-approved (marketed).

Related